Carl Zeiss Meditec AG has confirmed that Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group in Sweden, will take over as CEO on December 1, 2026. On the same date, she will join the Executive Board of Carl Zeiss AG with responsibility for the Medical Technology segment. Her appointment as successor to current CEO Andreas Pecher was first announced in May 2026. With the start date now confirmed, she will assume leadership from Pecher, who has served as interim CEO since January 1, 2026.
“I am delighted to join Carl Zeiss Meditec and the ZEISS Group. The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company’s transformation,” said Bronwyn Brophy O’Connor.
Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG, said: “With Bronwyn Brophy O’Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company. We wish her a great start.” He also thanked Andreas Pecher for his temporary dual role as CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG, and for providing important momentum during this period.
Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG, added: “With her excellent skills, Bronwyn Brophy O’Connor will now be able to further advance the strategy and transformation of the Medical Technology segment forward and contribute to the success of the ZEISS Group.”
Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise Bronwyn Brophy O’Connor as CEO and Justus Wehmer as CFO. The Executive Board of Carl Zeiss AG will comprise Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment).
Brophy O’Connor studied at Dublin City University in Ireland, earning a bachelor’s degree in International Marketing and Languages (Spanish and French) and an MBA in 2002. She began her career at Johnson & Johnson in 1997, serving in roles of increasing seniority and ending as General Manager of the Cardiovascular Care Group for the U.K. & Ireland in 2012. She then joined Covidien, later acquired by Medtronic, serving from 2013 to 2018 as Vice President Early Technologies EMEA and later as President Women’s Health at Medtronic in Boston. In 2019, she joined Thermo Fisher Scientific as President for the EMEA region and a year later was promoted to Global President of the Immunodiagnostics Division in Uppsala, Sweden. She has worked internationally in Ireland, Spain, the U.K., Switzerland, Sweden and the U.S. Since 2023, she has been CEO of the Vitrolife Group, a global medtech company publicly listed on the NASDAQ Stockholm and headquartered in Gothenburg, Sweden.
The leadership change matters because Carl Zeiss Meditec is one of the world’s leading medical technology companies, supplying innovative technologies and application-oriented solutions designed to help doctors improve patients’ quality of life. With 5,784 employees worldwide, the Group generated revenue of EUR 2,228m in fiscal year 2024/25 (to 30 September). Its head office is in Jena, Germany, and more than 50 percent of its employees are based in the USA, Japan, Spain and France. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float, with approximately 59 percent held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information, visit the ZEISS newsroom or the Carl Zeiss Meditec website. The original release is available on NEWMEDIAWIRE.
